Royalty Pharma plc (RPRX) compared with its closest peers (SRPT, BMRN, ALNY, PAHC, ELAN): P/E 41.3 vs industry 17.2. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Sarepta Therapeutics, BioMarin Pharmaceutical, Alnylam Pharmaceuticals, Phibro Animal Health, Elanco Animal Health, Lakefront Biotherapeutics, Prestige Consumer Healthcare, Madrigal Pharmaceuticals, Ionis Pharmaceuticals and ANI Pharmaceuticals share Royalty Pharma's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | $1.98B | -3.0 |
| BioMarin Pharmaceutical Inc. (BMRN) | $12.91B | 176.9 |
| Alnylam Pharmaceuticals, Inc. (ALNY) | $31.53B | 108.0 |
| Phibro Animal Health Corporation (PAHC) | $1.49B | 15.6 |
| Elanco Animal Health Incorporated (ELAN) | $11.98B | 89.4 |
| Lakefront Biotherapeutics NV (LKFT) | $1.93B | 6.0 |
| Prestige Consumer Healthcare Inc. (PBH) | $2.43B | 14.1 |
| Madrigal Pharmaceuticals, Inc. (MDGL) | $11.94B | -45.4 |
| Ionis Pharmaceuticals, Inc. (IONS) | $9.93B | -33.2 |
| ANI Pharmaceuticals, Inc. (ANIP) | $1.65B | 15.3 |
| Stock P/E | 41.3 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 89.8% |
| vs Industry | 140.2% |
RPRX overview · RPRX earnings · RPRX financials · RPRX KPIs · RPRX documents · RPRX ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.